Medesis Pharma S.A.

Legal Proceedings Report • Jul 13, 2023

MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM

Final recruitment stage of the Nanolithium study in fall 2023, first results expected in Q1 2024

Montpellier, July 13, 2023 - 6 :00pm - MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® nanomicelle oral delivery féchnology,
announces its participation in the AAC (Alzheimer's Association International

Taking place in Amsterdam from July 16 to 20, 2023, the Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing the science of dementia.

Each year, AAIC brings together leading basic scientists, clinical
researchers and clinicians to share the latest discoveries that will with will will will will wi
diagnosis

Solène Guilliot, Chief Medical Officer and Head of R&D at Medesis Pharma will be on site to meet key players in the field and present a scientific poster describing the design of the Phase II study, currently in progress, aimed at demonstrating the effect of NanoLithium® on behavioral and psychological symptoms in patients with mild to severe Alzheimer's disease and explore the disease modifying potential.

Medesis Pharma's NanoLithium study program has been prepared with Professor Jacques Touchon, former Dean of the Montpellier Faculty of Medicine and President of the last World Alzheimer's Congresses in 2019, 2020 and 2021, who is also a member of the CTAD 2022 Scientific Committee and Medesis Pharma's Permanent Scientific Advisory Board.

The study on 68 Alzheimer's patients is ongoing in 8 university hospitals (CHU Montpellier, Toulouse, Paris, Tille, Childelline is and in original more included in the paint in the paint in include in the circular i line include in the circular in included in in included in included Q1 2024.

Medesis Pharma's proprietary Aonys® technology is a blend of lipid components that spontaneously selfstructure into a "waterinoil" microemusion. Aonys® enable the administration of low doses of water-soluble princemed by live ingreased hird his his habsar in miom of monity in modil mindin, minimidine mindin, minimidine moant in hommune in hommelin in hommelin in Amondal in Annand phenotypic results in mouse models.

For more information:

• Download Medesis Pharma's poster
• Visit AAIC conference website

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil CALYPTUS or military nuclear accident.

French biopharmaceurical company based near Montpellier, Medesis Pharma is the author of 15 scientific - Tel : +33 1 53 65 68 publications, holds 12 patent families and 72 patents, resulting from 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information: www.medesispharma.com

MEDESIS PHARMA

lean Claude Maurel Tel: +33 4 67 03 03 96 contact@medesispharma.com

Marie Calleux medesispharma@calyptus.net